<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------------
FORM 8-K
--------------------------
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) September 19, 2000
--------------------------
ALEXION PHARMACEUTICALS, INC.
-------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-27756 13-3648318
------------------------ --------------------- ---------------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
25 Science Park, New Haven, CT 06511
-------------------------------------------- -----------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (203) 776-1790
-----------------------
Not Applicable
-------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
ITEM 5. OTHER EVENTS
On September 19, 2000, Alexion Pharmaceuticals, Inc. issued the press
release filed herewith as Exhibit 99.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(C) EXHIBITS.
99 Press Release dated September 19, 2000.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ALEXION PHARMACEUTICALS, INC.
Date: September 19, 2000 By: /s/ Leonard Bell, M.D.
------------------------------
Name: Leonard Bell, M.D.
Title: President, Chief Executive
Officer, Secretary and
Treasurer
